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The LKB1 and AMPK proteins participate in an energy sensing cascade that responds to depletion of
ATP, serving as a master regulator of metabolism that inhibits anabolic processes and stimulates
catabolic processes. However in recent years, LKB1 and AMPK have been implicated in a variety of
other cellular processes, both cytoplasmic and nuclear, such as control of cell polarity and regula-
tion of gene transcription. In this review, we summarize the most recent discoveries regarding par-
ticipation of LKB1 and AMPK in signaling pathways that respond to cellular stress and damage, and
the relevance of this signaling for disease and therapy.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The LKB1–AMPK pathway has until fairly recently been thought
of as primarily an energy sensing pathway engaged by cells in re-
sponse to low energy levels. More recently, LKB1 and AMPK have
been linked to many other fundamental cellular processes includ-
ing regulation of cell proliferation, cell polarity, migration, tran-
scription and cellular stress and damage responses, the focus of
this mini-review.
2. Discovery and characterization of LKB1 and AMPK
Liver kinase B1 (LKB1)was discovered only 12 years ago, as a ser-
ine–threoninekinase that ismutated inPeutz-Jeghers Syndrome [1].
Peutz-Jeghers Syndrome is a rare autosomal dominant hamartoma
syndrome, predisposing patients to multiple benign and malignant
tumors including gastrointestinal, pancreatic and lung tumors [2].
Initially, studies to identify the function of LKB1 were difﬁcult, as
its sequence gave few clues as to its activity. Overall it had little
similarity to other protein kinases. However, studies in cell lines
includingHeLaS3andG361melanomacells,which lack endogenous
LKB1, provided insights into LKB1’s role as a tumor suppressor,
including early evidence of its role in stress and damage responses.chemical Societies. Published by E
lecular Carcinogenesis, The
mithville, TX 78957, United
alker).2.1. LKB1 regulation of p53 activity
LKB1 physically associates with p53 upon DNA damage (UVC
radiation), and localizes to the p21 promoter region in tandem
with p53 [3]. Additional interactions with this damage-response
tumor suppressor occur at the level of post-translational modiﬁca-
tion of p53, with both LKB1 and AMPK acting as kinases for p53 at
the serine (Ser) 15 phosphorylation site; LKB1 also phosphorylates
p53 at Ser 392, which increases p53 protein stability [3,4].
2.2. LKB1 signaling to AMPK
More recently, LKB1 has been appreciated to be a signaling pro-
tein, integrating cellular energy sensing with growth and prolifer-
ation, functioning both in the nucleus and the cytoplasm. It is
ubiquitously expressed throughout the body, and functions as a
heterotrimer with STRAD (sterile-20-related adaptor) and MO25
(mouse protein-25) in cells [5]. LKB1 is post-translationally modi-
ﬁed by kinases in several signaling pathways including cAMP–PKA,
the ERK–RSK pathway and ATM, a DNA damage sensor, as re-
viewed in [6]. Despite the fact that it is constitutively active in cells
[7], it has also been noted that LKB1 catalytic activity is enhanced
when STRAD and MO25 are present in the complex [5].
AMP-activated protein kinase (AMPK) is one of the best charac-
terized substrates of LKB1. AMPK is a heterotrimer that consists of
a catalytic subunit, AMPKa, and 2 regulatory subunits, AMPKb and
AMPKc. There are 2 distinct isoforms of the AMPKa subunit
designated AMPKa1 and AMPKa2, which differ in their tissuelsevier B.V. All rights reserved.
A. Alexander, C.L. Walker / FEBS Letters 585 (2011) 952–957 953speciﬁcity, subcellular localization and mechanisms of activation.
While AMPKa1 is widely expressed, AMPKa2 is restricted mainly
to skeletal muscle, cardiac muscle and liver cells, where it is highly
expressed [8]. On a cellular level under basal conditions, AMPKa1
appears mainly cytoplasmic whereas AMPKa2 is primarily local-
ized to the nucleus. The yeast AMPK homolog, Snf1, is also predom-
inantly located in the nucleus [9]. It is currently unclear how the
AMPK complex containing a2 localizes to the nucleus, since no
classical nuclear localization sequence has been found, and the
63 kDa protein is probably too large to passively diffuse through
the nuclear pore.
2.3. How is AMPK activated?
At present, a number of stimuli are known to activate AMPK,
some of which are related to energy sensing (such as glucose depri-
vation), as well as others that are not (such as hyperosmotic
stress). When cellular energy levels are depleted, and the AMP:ATP
ratio rises, AMPK is activated via allosteric binding of AMP to the
AMPKc subunit, which has been proposed to induce a conforma-
tional change in the complex, improving the ability of AMPKa-sub-
unit to serve as a substrate for upstream kinases [6]. The primary
activation site on the catalytic component AMPKa is threonine
(Thr) 172, and while both a1 and a2 can be phosphorylated at this
site by the same upstream kinases, a2 subunit phosphorylation is
more AMP-dependent [9].
LKB1 has now been shown to be one of the primary kinases that
phosphorylates AMPK. AMPK activation by agonists such as 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR), metfor-
min or phenformin or in response to stress is absent in LKB1-deﬁ-
cient cells [5], identifying LKB1 as an obligatory AMPK kinase in
this setting. Activation of AMPK by AICAR occurs via mono-phos-
phorylation of AICAR to its active form, ZMP which can mimic
the effect of AMP on AMPK, i.e., allosteric activation and enhance-
ment of phosphorylation by upstream kinase(s) [10].
In addition to LKB1, the calmodulin-dependent protein kinases
CaMKKa and CaMKKb also function as kinases for Thr 172 of AMPK
[11–13]. This activation pathway is calcium-responsive, does not
require an increase in AMP, and is thought to be particularly
important for endocrine hormone regulation, for example adipo-
nectin activation of AMPK in vascular endothelial cells [14]. CaM-
kinases are most highly expressed in neural tissue, where they play
a role in activating AMPK in response to neuronal depolarization
caused by K+-increases and Ca2+ inﬂux [11].
2.4. AMPK signaling to mTORC1 and growth suppression
How does activation of LKB1 and AMPK result in growth sup-
pression? One of the key targets of these kinases is the TSC2–
mTORC1 signaling node. The tuberous sclerosis complex 2 (TSC2)
tumor suppressor is directly phosphorylated by AMPK at Thr
1227 and Ser 1345, which enhances its GTP-ase activity towards
Rheb, inactivating this small GTPase to decrease mTORC1 signaling
[15]. In addition to this TSC2-dependent pathway, AMPK has been
shown to directly phosphorylate raptor (a component of the
mTORC1 complex) to inhibit mTORC1 signaling [16]. The reciprocal
relationship between AMPK activity and mTORC1 activity allows
the cell to coordinate energy requiring anabolic processes with en-
ergy availability – under conditions of energy deprivation, activa-
tion of AMPK can limit energy-consuming processes such as
protein synthesis via repression of mTORC1.
In addition to protein synthesis and cell growth, mTORC1 is also
a key negative regulator of autophagy, the catabolic process of
breaking down cell components via the fusion of autophagosomes
with lysosomes, degrading the contents autophagosomes for recy-
cling by the cell [17]. Activation of AMPK induces autophagy bynegatively regulating mTORC1 via TSC2 or raptor, and thereby as-
sists the cell in generating building blocks for energy production
and other cellular processes. Recently, ULK1 has been identiﬁed
as a bona ﬁde AMPK substrate when cells undergo nutrient depri-
vation, providing a molecular link between this energy-sensing
pathway and regulation of autophagy [18,19].
In contrast to energy stress, DNA damage, which activates p53
via ATM/ATR phosphorylation, can both promote and inhibit
autophagy. In the nucleus, p53 functions as a transcription factor,
where it regulates the expression of many genes, including several
that participate in autophagy [20]. In the cytoplasm, p53 can inhi-
bit AMPK and autophagy, indicating that the relationship between
p53 and AMPK in regulation of autophagy is very complex and
likely context dependent [21].
A second pathway of AMPK-mediated regulation of autophagy
may be via the eEF-2 kinase (also known as Ca2+/calmodulin-
dependent kinase III) pathway. AMPK directly phosphorylates
and activates eEF-2 kinase, which inhibits protein synthesis at
the elongation stage [22]. The precise role that eEF-2 plays in
autophagy is still not known, however it was shown that knock-
down of eEF-2 inhibited autophagy in glioblastoma cells, whereas
overexpression increased autophagy. Finally, another less studied
AMPK-kinase, TAK1 (transforming growth factor b-activated
kinase 1) was shown to be induced in response to the apoptosis-
inducing agent TRAIL, resulting in a cytoprotective autophagy
response, which is dependent upon AMPKa1 [23]. It is clear from
these studies that AMPK plays important roles in signaling to reg-
ulate autophagy in response to diverse stress stimuli.
2.5. Other AMPK-related proteins
Analysis of the human kinome reveals a family of AMPK-related
proteins that contain activation loops that are homologous to
AMPK, suggesting they could also be targets of LKB1. This family
of proteins is now known to contain at least 12 validated LKB1 sub-
strates (not including AMPK) and 8 non-LKB1 substrates [6,24].
One of these AMPK-family members, SNARK, was discovered as a
gene induced in response to UV damage in rodent keratinocytes;
SNARK also expressed in a number of human tissues [25,26]. Upon
additional characterization, a broad range of stressors (including
glucose and glutamine deprivation, hydrogen peroxide, hyperos-
motic stress, ATP synthesis inhibitors such as oligomycin and
arsenite) were capable of activating SNARK kinase activity in a
cell-type speciﬁc manner. These results suggest that other AMPK-
family members also may function as stress responsive proteins.
It is unclear whether AMP directly activates all AMPK-related
proteins, although SNARK is activated by AICAR or glucose depriva-
tion in cells [25]. It is likely there are some cell-type differences in
activation mechanisms, since in contrast to the ﬁrst report on
SNARK (NUAK2) activation in neonatal rat keratinocytes and baby
hamster kidney cells [25], later studies showed that in mouse em-
bryo ﬁbroblasts (MEFs), AICAR and phenformin were unable to
activate SNARK [24]. While AMPK-related proteins are less well
studied than AMPK, it is already clear that they vary in their sub-
strate speciﬁcity, although not all these substrates have been char-
acterized. Future research on AMPK-related proteins will likely
expand our knowledge about how they are regulated, including
identiﬁcation of additional upstream kinases and regulatory phos-
phorylation sites, their physiological and pathological functions,
and identify additional substrates.3. Involvement in DNA damage response pathways
The kinase ATM lies upstream of LKB1 in damage response sig-
naling. ATM, the gene mutated in the disease ataxia-telangiectasia,
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important roles in sensing and responding to different types of
damage. In the nucleus, it is well appreciated that ATM is activated
by DNA double-strand breaks, leading to induction of cell cycle
checkpoints, DNA repair and if necessary, apoptosis if the damage
is too severe to be repaired. However, ATM has also been localized
to the cytoplasm, where it can be activated in the absence of DNA
damage [27,28]. Dario Alessi’s group in 2002 identiﬁed a series of
phosphorylation sites on LKB1, none of which affected LKB1’s ki-
nase activity towards p53, one of which, threonine 366 (Thr
366), lay within an ATM consensus phosphorylation motif. They
went on to show that ionizing radiation (which activates ATM)
led to phosphorylation of LKB1 at this site [29]. The function of this
phosphorylation site remained somewhat elusive since mutation
of this site to alanine had little affect on cell growth when transfec-
ted into LKB1-deﬁcient cells. However until recently, the impact of
phosphorylation at Thr 366 on downstream signaling to AMPK or
mTORC1 had not been studied further.
We have shown that a damage response signaling pathway ex-
ists from ATM to LKB1 that regulates AMPK in the cytoplasm [30].
In response to oxidative damage, cytoplasmic ATM is rapidly acti-
vated, phosphorylating LKB1 in the cytoplasm, activating AMPK,
TSC2 and suppressing mTORC1. As a consequence of this mTORC1
suppression, autophagy is induced, suggesting this pathway may
function as a mechanism to maintain redox homeostasis.
ATM has also been shown to directly phosphorylate AMPKa
independently of LKB1 on T172 in response to DNA damage (eto-
poside), which has been linked to mitochondrial biogenesis in a
variety of mammalian cell types [31]. While not deﬁnitively shown
in this paper, the authors proposed that in response to DNA dam-
age, AMPK was activated both by a decrease in ATP (increase in
AMP:ATP ratio) as well as by ATM phosphorylation. Induction of
mitochondrial biogenesis in response to DNA damage by a variety
of agents including chemotherapeutics and radiation (which can
damage mitochondria and release ROS, inducing oxidative dam-
age), coupled with autophagy of damaged mitochondria, may be
a mechanism for limiting cellular damage while ensuring sufﬁcient
energy to carry out the important repair pathways necessary for
survival. Apart from the DNA damage response, AMPK has also
been linked to mitochondrial biogenesis in skeletal muscle in re-
sponse to chronic energy deprivation or endurance training exer-
cises [32]. The mechanisms responsible involve master regulators
of mitochondrial biogenesis including the peroxisome proliferator
activator receptor c coactivator 1a, and calcium/calmodulin-
dependent protein kinase IV [32].
A second DNA damage-induced pathway for AMPK activation
involves p53 [33]. Two recently-identiﬁed p53 transcriptional tar-
gets, sestrin 1 and sestrin 2 were shown to mediate AMPK activa-
tion and mTORC1 suppression by DNA damage (speciﬁcally
camptothecin in vitro and the hepatocarcinogen diethylnitros-
amine in vivo). While the precise mechanism of AMPK activation
by sestrins was not analyzed, this pathway was p53-dependent,
and resulted in the formation of large protein complexes contain-
ing sestrins, AMPK, TSC2, and TSC1, suggesting that the sestrins
may function as adaptor proteins to bring together these proteins,
promoting AMPK activation of TSC2/1 and mTORC1 repression.
4. Regulation of cell death pathways
4.1. Interactions with p53 family members
Apart from autophagy, AMPK activation in response to DNA
damage may regulate apoptosis or other cell death pathways. For
example, the chemotherapeutic drug cisplatin, which damages
DNA by forming intrastrand crosslinks, has been shown to activate
AMPK in several tumor types including colon cancer, gastric cancerand glioma [34,35]. In one study, AMPK activation by cisplatin cor-
related with ROS generation, and resulted in enhanced survival. In
this setting, as would be predicted, inhibition of AMPK sensitized
the cells to cisplatin-induced apoptosis, which was preceded by a
dramatic decrease in ATP levels [34]. This pathway was dependent
on p53, and involved hyper-phosphorylation of p53 at Ser 15 by
ERK, which occurred in the presence of AMPK inhibition. Interest-
ingly, when a panel of different tumor lines were treated with a
relatively high dose of cisplatin, highly chemosensitive cells such
as HeLa, which are LKB1-null, were refractory to AMPK activation,
whereas more resistant cells exhibited AMPK activation, suggest-
ing a role for LKB1 signaling to AMPK in a survival pathway. Thus
in the context of cytotoxic therapy, it is possible that inhibition of
LKB1/AMPK in p53-proﬁcient cells may reduce survival and im-
prove cell killing.
In addition to p53, other members of this transcription factor
family are phosphorylated by AMPK in response to DNA damage.
For example, AMPKa interacts with both p73a and p63a, with
multiple functional consequences, including altering subcellular
localization of AMPKa subunits [36]. Under normal conditions,
endogenous AMPKa1 is mainly cytoplasmic, whereas AMPKa2 is
nuclear [9,37,38]. However, when exogenous p73a is overexpres-
sed, both AMPKa1 and AMPKa2 localize to the nucleus, where
AMPK:p73a complexes act as transcriptional co-repressors. This
was directly shown by overexpressing AMPKa1 or AMPKa2, and
measuring luciferase activity at p53-family responsive promoters
such as the Bax promoter. Using these luciferase reporters as read-
outs of transcriptional activity, Lee et al. showed that increasing
expression of AMPKa1 or AMPKa2 resulted in inhibition of
p73a-mediated repression of gene expression. Interestingly, the ki-
nase activity of AMPK was not required for this activity. Further
evidence of in vivo relevance of this observation was obtained
using ChIP assays of the endogenous p21 promoter, which could
immunoprecipitated with antibodies directed against AMPKa2.
Importantly, this AMPK-mediated p73a transcriptional repression
was shown to enhance survival in response to DNA damage, with
cells overexpressing AMPK2a resistant to cisplatin-induced apop-
tosis [36].
4.2. Other nuclear functions of AMPK
Histone H2B has also been identiﬁed recently as an AMPKa2
stress-response substrate [39]. When AMPK is activated by a vari-
ety of DNA damaging agents and stressors such as 2-deoxyglucose,
histone H2B is phosphorylated at Ser 36, inducing transcription of
a large number of stress-inducible genes. This pathway for direct
modiﬁcation of chromatin by AMPK allows this kinase to partici-
pate in a global transcriptional response in addition to directly
phosphorylating speciﬁc transcription factors, which may allow
cells to ﬁne-tune gene expression to survive damage and stress.
4.3. Regulation of p27 stability and localization
Both cell death (apoptosis) and survival (autophagy) are regu-
lated by AMPK in response to the stress of glucose deprivation.
One of the key regulators of this ‘‘life or death’’ decision down-
stream of AMPK is p27, a cyclin-dependent kinase inhibitor (CKI)
and a direct substrate for AMPK in response to serum starvation
or 2-deoxyglucose treatment [40]. AMPK phosphorylation of p27
at the carboxy-terminal threonine (Thr 198 in humans) results in
increased protein stability and combined with cytoplasmic locali-
zation of this CKI, promotes autophagy. However, in cells depleted
of p27, glucose deprivation induces apoptosis, demonstrating that
p27-dependent autophagy functions downstream of AMPK as a
survival mechanism under conditions of energetic stress. AMPK
also phosphorylates p27 at its nuclear localization signal (NLS),
A. Alexander, C.L. Walker / FEBS Letters 585 (2011) 952–957 955causing p27 to be sequestered in the cytoplasm away from its nu-
clear substrates (such as cdk2), inhibiting its function as a CKI [41].
This ﬁnding has potential implications for cancer therapy, since
many targeted therapies such as anti-angiogenic agents, or even
traditional cytotoxic agents induce stress responses that can acti-
vate AMPK, potentially inducing this p27-dependent autophagic
survival mechanism.Fig. 1. Schematic showing activation of LKB1 and AMPK by diverse stresses and the
phosphorylation sites that are targeted by the upstream kinase.5. Tissue-speciﬁc damage response roles for LKB1 and AMPK
5.1. LKB1–AMPK signaling in cardiac function
Studies from LKB1 and AMPK knockout mice, and the discovery
of human disease-causing mutations in AMPK, have pointed to an
important role for these signaling kinases in cardiac protection.
The LKB1 cardiac-myocyte speciﬁc knockout mouse develops a car-
diac hypertrophic phenotype by 12 weeks of age, and eventually
succumbs to cardiac failure by 6 months [42]. As expected, hearts
from LKB1-knockout mice have elevated mTORC1 signaling leading
to increased protein synthesis, likely contributing to hypertrophy.
In contrast to LKB1-knockout models, mice lacking AMPKa1 or
AMPKa2, do not have a baseline cardiac hypertrophy phenotype,
however upon stress from pressure overload, AMPKa2 knockout
mice can develop left ventricular hypertrophy [43].
One of the key roles that AMPK plays in cardiac muscle is in the
response to hypoxia/ischemia. Since the heart is a highly metabolic
organ that requires signiﬁcant energy for continuous function, the
ability to temporarily deal with stress from hypoxia is essential to
maintain function.When blood supply to the heart is compromised,
AMPK is activated, stimulating fatty acid oxidation, glucose uptake
and glycolysis to generate ATP needed for continued function. Con-
sistent with the key role of AMPK in this process, mice expressing a
kinase-dead form of AMPK are more susceptible to damage from
ischemia and exhibit delayed recovery during reperfusion [44].
Hypoxia, such as induced by ischemia, signals to mTORC1 via
both AMPK-dependent and independent pathways. It has recently
been shown that activation of AMPK by hypoxia is independent of
energy levels, but involves generation of ROS [45]. While severe
hypoxia or anoxia (0% O2) does inhibit mitochondrial respiration
and induce AMPK activation by decreasing energy levels, acute hy-
poxia (deﬁned as 1–2% O2) does not signiﬁcantly alter the AMP:ATP
ratio, suggesting other mechanisms are involved in activating
AMPK. Another pathway that is engaged in response to hypoxia
to inhibit mTORC1 signaling involves upregulation of Redd1 (regu-
lated in DNA damage-1) and activation of TSC2 [46,47].
5.2. Role of AMPK signaling in the brain
Similar to the heart, the brain has a high basal metabolic rate,
utilizing more than 50% of the total glucose in the body. It is exqui-
sitely sensitive to changes in the supply of glucose or oxygen, both
of which can activate AMPK. AMPK activation in the brain has been
linked to survival in response to different types of stress including
glucose depletion, oxidative stress generated by amyloid b peptide
and glutamate [48]. While the precise mechanisms for this protec-
tion have not been identiﬁed, some potential AMPK targets such as
HMG-CoA and Raf1 (an upstream kinase of the MAPK pathway)
have been hypothesized to be involved. It is thought that the CaM-
KK pathway for AMPK activation is particularly relevant in this
tissue due to the frequent cycling of Ca2+ levels when K+ depolar-
ization occurs [11]. If so, it suggest that targeting this pathway
pharmacologically could provide a novel therapeutic strategy for
treating chronic neurodegenerative conditions.
Recently, in an experimental model of cholesterol-induced
neurotoxicity, AMPK was shown to play a role in reversing someof the pathological changes induced by a high-cholesterol diet,
including elevation of ROS, inﬂammation and amyloid b deposition
[49]. Quercetin, a naturally occurring ﬂavonoid found at high levels
in green and black teas was shown to decrease ROS and other
markers of tissue damage in these mice, in part via activating
AMPK, which resulted in cognitive improvement. At the molecular
level, quercetin activated AMPK via decreasing the expression of
the PP2C phosphatase. In cells with elevated ROS (such as ATM-
or TSC2-deﬁcient cells), we showed that rapamycin, a drug that
inhibits mTORC1, decreased ROS to baseline levels [30]. It is likely
that quercetin acts in a similar mechanism, since AMPK activation
results in repression of mTORC1 activity. Further work is necessary
to determine whether this pathway is the main factor responsible
for the reversal of disease symptoms. In addition, prior to moving
forward with clinical trials in humans to treat Alzheimer’s with
drugs that activate AMPK, it will be important to understand more
fully the role of AMPK signaling in response to these drugs, as it
also has been reported recently that metformin increases amyloid
b deposition, opening the possibility that in elderly patients AMPK
activation could have harmful effects in the brain [50].
5.3. DNA-damage induced LKB1 activation in B cells
LKB1 activation in response to DNA damage may play a special-
ized role in the immune system. After V(D)J recombination in the
bone marrow, B-cell differentiation continues in the lymph node
to generate the 109 clones of B-cells found in humans recognizing
different antigens. In the germinal centers, the B cells rapidly pro-
liferate and hypermutate the variable region of the immunoglobu-
lin gene, in a class switch recombination process requiring
activation-induced cytidine deaminase (AID). This AID activity
generates double-strand breaks, which activate the DNA damage
response, and likely contributes to lymphomagenesis. A recent re-
port by Sherman et al. showed that AID induced ATM activation
and LKB1 phosphorylation [51]. LKB1 phosphorylation of the CREB
transcriptional coactivator (CRTC2) resulted in cytoplasmic
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tion and promote B cell differentiation. Interestingly, CRTC2 has
also been shown to be phosphorylated by the AMPK-family mem-
bers MARK2 and SIK2 in pancreatic beta cells, highlighting this
pathway as an important mediator of LKB1/AMPK activity [52].
6. Summary
Taken together, it is apparent that LKB1 and AMPK, initially
identiﬁed as participating in energy sensing in the cell, also play di-
verse roles in cellular responses to many types of stress. As illus-
trated in Fig. 1, the LKB1–AMPK pathway plays critical roles in
regulating important life-and-death processes including apoptosis
and autophagy, which may function in a tissue-speciﬁc manner,
such as cardioprotection from damage in the heart. As we develop
a more detailed understanding of how these kinases function in
normal physiology, and are their role in pathophysiology and dis-
ease, it is likely that their utility as therapeutic targets will in-
crease. Thus, both LKB1 and its target AMPK, hold promise as
therapeutic targets to treat, and possibly prevent, many diseases
including neurodegeneration, cardiovascular disease and cancer.
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